C4U and Noile-Immune Biotech partnership on PRIME allogeneic CAR-T cell therapy

(Yamaguchi University) Noile-Immune Biotech and C4U have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U's CRISPR/Cas3 genome editing technology and Noile-Immune's PRIME technology designed to improve proliferation and trafficking of immune cells into solid tumors. The alliance is aiming to create PRIME Allogeneic CAR-T cells that are highly versatile and beneficial for many solid cancer patients.